Central lab Services Clinical Trial Lab Services Market - Global Forecast To 2030
商品番号 : SMB-75324
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年3月 |
| ページ数 | 311 |
| 図表数 | 365 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.
世界の中央ラボサービス/臨床試験ラボサービス市場は、予測期間中に6.5%のCAGRで成長し、2025年の59億7,000万米ドルから2030年までに81億8,000万米ドルに達すると予測されています。
This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.
これは、新薬発見の採用が増えているためであり、採用が増えるにつれて、これらのサービスの需要が高まります。さらに、ヘルスケアへの助成金を提供するための政府のサポートが増加しているため、臨床試験の数が増加し、結果として中央ラボ臨床サービス試験の需要が増加しています。ただし、臨床試験方法に関連する高コストが市場の主な制約となっています。さらに、訓練を受けたヘルスケア専門家の不足とサービスに関する限られた知識は、市場の成長にとって大きな課題です。しかし、2025〜2030年の予測期間にわたって市場拡大につながる環境が生まれています。
“The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period.”
Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.
“The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market.”
Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.
“Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region.”
The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country’s growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
- By Designation: C-level–25%, Director-level–30% and Others–45%
- By Region: North America–40%, Europe–25%, Asia Pacific–20%, Latin America- 10%, and Middle east and Africa – 5%
Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Société Générale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).
Research Coverage
This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 32
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 32
1.3.2 INCLUSIONS AND EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 37
2.1.2.1 Primary sources 37
2.1.2.2 Key industry insights 38
2.1.2.3 Key data from primary sources 38
2.1.2.4 Breakdown of primary interviews 40
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
2.2.1.1 Approach 1: Company revenue estimation approach 41
2.2.1.2 Approach 2: Presentations of companies and primary interviews 41
2.2.1.3 Approach 3: Primary interviews 41
2.2.1.4 Growth forecast 41
2.2.1.5 CAGR projections 42
2.2.2 TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43
2.4 RESEARCH ASSUMPTIONS 45
2.4.1 STUDY-RELATED ASSUMPTIONS 45
2.4.2 PARAMETRIC ASSUMPTIONS 45
2.5 RESEARCH LIMITATIONS 46
2.6 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 52
4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW 52
4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER AND COUNTRY 53
4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY 54
4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing number of clinical trials 57
5.2.1.2 Rising investments in research & development 57
5.2.1.3 Growing prevalence of rare diseases 58
5.2.1.4 Favorable government initiatives 59
5.2.2 RESTRAINTS 59
5.2.2.1 High costs associated with clinical trials 59
5.2.2.2 Shortage of skilled professionals 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Emerging markets worldwide 61
5.2.3.2 Decentralized and virtual clinical trials 61
5.2.4 CHALLENGES 62
5.2.4.1 Regulatory complexities 62
5.2.4.2 Limited patient diversity 63
5.2.4.3 Cybersecurity and intellectual property concerns 63
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64
5.4 VALUE CHAIN ANALYSIS 65
5.4.1 RESOURCE ACQUISITION AND PREPARATION 65
5.4.2 CLINICAL TRIAL EXECUTION 65
5.4.3 DATA REPORTING AND RESULT SUBMISSION 65
5.4.4 PROMOTION AND REGULATORY FILING 65
5.5 ECOSYSTEM ANALYSIS 66
5.6 INVESTMENT AND FUNDING SCENARIO 68
5.7 TECHNOLOGY ANALYSIS 68
5.7.1 KEY TECHNOLOGIES 68
5.7.1.1 Enzyme-linked immunosorbent assay 68
5.7.2 ADJACENT TECHNOLOGIES 69
5.7.2.1 Next-generation sequencing 69
5.8 KEY CONFERENCES AND EVENTS, 2025–2026 70
5.9 CASE STUDY ANALYSIS 71
5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH) 71
5.10 REGULATORY LANDSCAPE 72
5.10.1 REGULATORY FRAMEWORK 72
5.10.1.1 North America 72
5.10.1.2 Europe 73
5.10.1.3 Asia Pacific 73
5.10.1.4 Rest of the World 74
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.11 PORTER’S FIVE FORCES ANALYSIS 81
5.11.1 THREAT OF NEW ENTRANTS 82
5.11.2 THREAT OF SUBSTITUTES 82
5.11.3 BARGAINING POWER OF SUPPLIERS 82
5.11.4 BARGAINING POWER OF BUYERS 82
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 83
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.12.2 BUYING CRITERIA 84
5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 85
5.13.1 INTRODUCTION 85
5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES 85
5.13.3 AI USE CASES 86
5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM 87
6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE 88
6.1 INTRODUCTION 89
6.2 PHASE I 89
6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH 89
6.3 PHASE II 91
6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET 91
6.4 PHASE III 94
6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET 94
6.5 PHASE IV 96
6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH 96
7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE 100
7.1 INTRODUCTION 101
7.2 SAFETY TESTING 101
7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH 101
7.3 IMMUNOLOGY 103
7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH 103
7.4 GENETIC TESTING 105
7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET 105
7.5 COAGULATION TESTING 107
7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH 107
7.6 PATHOLOGY TESTING 109
7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH 109
7.7 BIOMARKERS 112
7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH 112
7.8 COMPANION DIAGNOSTICS 113
7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET 113
7.9 OTHER TESTS 116
8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA 118
8.1 INTRODUCTION 119
8.2 ONCOLOGY 119
8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH 119
8.3 INFECTIOUS DISEASES 121
8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH 121
8.4 NEUROLOGY 124
8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH 124
8.5 CARDIOLOGY 126
8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET 126
8.6 OTHER THERAPEUTIC AREAS 128
9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY 131
9.1 INTRODUCTION 132
9.2 SMALL MOLECULES 132
9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH 132
9.3 BIOLOGICS 134
9.3.1 MONOCLONAL ANTIBODIES 136
9.3.1.1 Growing advancements in antibody engineering to drive market 136
9.3.2 VACCINES 138
9.3.2.1 Increasing investments in vaccine development to favor growth 138
9.3.3 OTHER THERAPEUTIC PRODUCTS 140
9.4 CELL & GENE THERAPY 142
9.4.1 OUTSOURCING TREND TO FAVOR GROWTH 142
9.5 MEDICAL DEVICES & IVD DEVICES 144
9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET 144
10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER 147
10.1 INTRODUCTION 148
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 148
10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH 148
10.3 CLINICAL RESEARCH ORGANIZATIONS 151
10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET 151
10.4 MEDICAL DEVICE COMPANIES 153
10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH 153
10.5 OTHER END USERS 155
11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY REGION 157
11.1 INTRODUCTION 158
11.2 NORTH AMERICA 158
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 159
11.2.2 US 164
11.2.2.1 Increasing clinical trials to support growth 164
11.2.3 CANADA 168
11.2.3.1 Rising incidence of chronic diseases to advance growth 168
11.3 EUROPE 172
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 173
11.3.2 GERMANY 177
11.3.2.1 Increasing healthcare expenditure to intensify growth 177
11.3.3 FRANCE 181
11.3.3.1 Growing investments in life sciences sector to boost market 181
11.3.4 UK 184
11.3.4.1 High number of oncology clinical trials to facilitate growth 184
11.3.5 ITALY 188
11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth 188
11.3.6 SPAIN 192
11.3.6.1 Emerging biotech companies to bolster growth 192
11.3.7 REST OF EUROPE 195
11.4 ASIA PACIFIC 199
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 199
11.4.2 JAPAN 204
11.4.2.1 Growing demand for drug development to propel market 204
11.4.3 CHINA 208
11.4.3.1 Booming pharmaceutical industry to drive market 208
11.4.4 INDIA 212
11.4.4.1 Increasing regulatory reforms to foster growth 212
11.4.5 REST OF ASIA PACIFIC 216
11.5 LATIN AMERICA 219
11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH 219
11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 221
11.6 MIDDLE EAST & AFRICA 224
11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET 224
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 225
12 COMPETITIVE LANDSCAPE 229
12.1 OVERVIEW 229
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 229
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 229
12.3 REVENUE ANALYSIS, 2020−2024 231
12.4 MARKET SHARE ANALYSIS, 2024 233
12.5 COMPANY VALUATION AND FINANCIAL METRICS 235
12.6 BRAND/PRODUCT COMPARISON 236
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 237
12.7.1 STARS 237
12.7.2 EMERGING LEADERS 237
12.7.3 PERVASIVE PLAYERS 237
12.7.4 PARTICIPANTS 237
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 239
12.7.5.1 Company footprint 239
12.7.5.2 Region footprint 240
12.7.5.3 Product type footprint 241
12.7.5.4 Therapeutic area footprint 242
12.7.5.5 Phase footprint 243
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 244
12.8.1 PROGRESSIVE COMPANIES 244
12.8.2 RESPONSIVE COMPANIES 244
12.8.3 DYNAMIC COMPANIES 244
12.8.4 STARTING BLOCKS 244
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 246
12.8.5.1 Detailed list of key startups/SMEs 246
12.8.5.2 Competitive benchmarking of key startups/SMEs 247
12.9 COMPETITIVE SCENARIO 248
12.9.1 PRODUCT LAUNCHES 248
12.9.2 DEALS 249
12.9.3 EXPANSIONS 250
12.9.4 OTHER DEVELOPMENTS 250
13 COMPANY PROFILES 251
13.1 KEY PLAYERS 251
13.1.1 THERMO FISHER SCIENTIFIC INC. 251
13.1.1.1 Business overview 251
13.1.1.2 Products/Services offered 252
13.1.1.3 Recent developments 253
13.1.1.3.1 Product launches 253
13.1.1.3.2 Deals 253
13.1.1.3.3 Expansions 254
13.1.1.4 MnM view 254
13.1.1.4.1 Key strengths 254
13.1.1.4.2 Strategic choices 254
13.1.1.4.3 Weaknesses and competitive threats 254
13.1.2 IQVIA 255
13.1.2.1 Business overview 255
13.1.2.2 Products/Services offered 256
13.1.2.3 Recent developments 257
13.1.2.3.1 Product launches 257
13.1.2.3.2 Deals 258
13.1.2.4 MnM view 258
13.1.2.4.1 Right to win 258
13.1.2.4.2 Strategic choices 258
13.1.2.4.3 Weaknesses and competitive threats 258
13.1.3 ICON PLC 259
13.1.3.1 Business overview 259
13.1.3.2 Products/Services offered 260
13.1.3.3 Recent developments 260
13.1.3.3.1 Product launches 260
13.1.3.3.2 Deals 261
13.1.3.4 MnM view 261
13.1.3.4.1 Right to win 261
13.1.3.4.2 Strategic choices 261
13.1.3.4.3 Weaknesses and competitive threats 261
13.1.4 CHARLES RIVER LABORATORIES 262
13.1.4.1 Business overview 262
13.1.4.2 Products/Services offered 263
13.1.4.3 Recent developments 264
13.1.4.3.1 Deals 264
13.1.4.3.2 Expansions 265
13.1.4.4 MnM view 265
13.1.4.4.1 Right to win 265
13.1.4.4.2 Strategic choices 265
13.1.4.4.3 Weaknesses and competitive threats 265
13.1.5 LABCORP 266
13.1.5.1 Business overview 266
13.1.5.2 Products/Services offered 267
13.1.5.3 Recent developments 268
13.1.5.3.1 Product launches 268
13.1.5.3.2 Deals 268
13.1.5.3.3 Expansions 269
13.1.5.3.4 Other developments 269
13.1.5.4 MnM view 270
13.1.5.4.1 Key strengths 270
13.1.5.4.2 Strategic choices 270
13.1.5.4.3 Weaknesses and competitive threats 270
13.1.6 QUEST DIAGNOSTICS 271
13.1.6.1 Business overview 271
13.1.6.2 Products/Services offered 272
13.1.6.3 Recent developments 272
13.1.6.3.1 Deals 272
13.1.7 MEDPACE 274
13.1.7.1 Business overview 274
13.1.7.2 Products/Services offered 275
13.1.7.3 Recent developments 275
13.1.7.3.1 Expansions 275
13.1.8 FRONTAGE LABS 276
13.1.8.1 Business overview 276
13.1.8.2 Products/Services offered 277
13.1.9 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA 279
13.1.9.1 Business overview 279
13.1.9.2 Products/Services offered 280
13.1.9.3 Recent developments 281
13.1.9.3.1 Deals 281
13.1.10 EUROFINS SCIENTIFIC 282
13.1.10.1 Business overview 282
13.1.10.2 Products/Services offered 283
13.1.10.3 Recent developments 284
13.1.10.3.1 Deals 284
13.1.11 REPROCELL INC. 285
13.1.11.1 Business overview 285
13.1.11.2 Products/Services offered 285
13.1.11.3 Recent developments 286
13.1.11.3.1 Deals 286
13.1.12 ACM GLOBAL LABORATORIES 287
13.1.12.1 Business overview 287
13.1.12.2 Products/Services offered 287
13.1.12.3 Recent developments 288
13.1.12.3.1 Deals 288
13.2 OTHER PLAYERS 289
13.2.1 WORLDWIDE CLINICAL TRIALS 289
13.2.2 VERSITI 290
13.2.3 CTI CLINICAL TRIAL & CONSULTING 291
13.2.4 CLARITY LABORATORIES, INC 292
13.2.5 NOVOTECH 293
13.2.6 ARUP LABORATORIES 294
13.2.7 PRECISION MEDICINE GROUP 295
13.2.8 BIOAGILYTIX LABS 296
13.2.9 CERBA HEALTHCARE 297
13.2.10 ALMAC GROUP 298
13.2.11 MLM MEDICAL LABS 299
13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP 300
13.2.13 UNILABS 301
14 APPENDIX 302
14.1 DISCUSSION GUIDE 302
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 307
14.3 CUSTOMIZATION OPTIONS 309
14.4 RELATED REPORTS 309
14.5 AUTHOR DETAILS 310
LIST OF TABLES
TABLE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
INCLUSIONS AND EXCLUSIONS 33
TABLE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
RISK ASSESSMENT 46
TABLE 3 TRADITIONAL VS. VIRTUAL CLINICAL TRIALS 62
TABLE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
ROLE OF COMPANIES IN ECOSYSTEM 67
TABLE 5 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
KEY CONFERENCES AND EVENTS, 2025−2026 70
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 11 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 78
TABLE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 84
TABLE 14 KEY BUYING CRITERIA, BY END USER 84
TABLE 15 KEY COMPANIES IMPLEMENTING AI 86
TABLE 16 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 89
TABLE 18 COMPANIES PROVIDING PHASE I SERVICES 90
TABLE 19 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I,
BY REGION, 2022–2030 (USD MILLION) 90
TABLE 20 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 90
TABLE 22 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 91
TABLE 23 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 91
TABLE 24 COMPANIES PROVIDING PHASE II SERVICES 92
TABLE 25 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY REGION, 2022–2030 (USD MILLION) 92
TABLE 26 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 93
TABLE 27 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 93
TABLE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 94
TABLE 29 COMPANIES PROVIDING PHASE III SERVICES 95
TABLE 30 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY REGION, 2022–2030 (USD MILLION) 95
TABLE 31 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 95
TABLE 32 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 96
TABLE 33 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 96
TABLE 34 COMPANIES PROVIDING PHASE IV SERVICES 97
TABLE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY REGION, 2022–2030 (USD MILLION) 98
TABLE 36 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 98
TABLE 37 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 99
TABLE 38 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 99
TABLE 39 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 101
TABLE 40 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY REGION, 2022–2030 (USD MILLION) 102
TABLE 41 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 102
TABLE 42 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 103
TABLE 43 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 103
TABLE 44 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY REGION, 2022–2030 (USD MILLION) 104
TABLE 45 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 104
TABLE 46 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 47 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 48 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION) 106
TABLE 49 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 50 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 107
TABLE 51 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 107
TABLE 52 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION) 108
TABLE 53 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 108
TABLE 54 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 109
TABLE 55 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 109
TABLE 56 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY REGION, 2022–2030 (USD MILLION) 110
TABLE 57 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 110
TABLE 58 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 111
TABLE 59 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 111
TABLE 60 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY REGION, 2022–2030 (USD MILLION) 112
TABLE 61 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 112
TABLE 62 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 113
TABLE 63 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION) 113
TABLE 64 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION) 114
TABLE 65 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 66 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 67 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 68 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY REGION, 2022–2030 (USD MILLION) 116
TABLE 69 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 70 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 71 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 72 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 119
TABLE 73 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION) 120
TABLE 74 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 75 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 76 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 77 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION) 122
TABLE 78 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 79 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 80 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 81 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2030 (USD MILLION) 124
TABLE 82 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 83 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 84 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 85 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION) 126
TABLE 86 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 87 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 88 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 89 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2030 (USD MILLION) 129
TABLE 90 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 91 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 92 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 93 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 132
TABLE 94 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2022–2030 (USD MILLION) 133
TABLE 95 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 96 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 97 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 98 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 135
TABLE 99 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY REGION, 2022–2030 (USD MILLION) 135
TABLE 100 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 101 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 102 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 103 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2030 (USD MILLION) 137
TABLE 104 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 137
TABLE 105 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 106 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 107 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 108 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 139
TABLE 109 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 110 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 111 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2022–2030 (USD MILLION) 141
TABLE 112 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 113 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 142
TABLE 114 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 142
TABLE 115 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2030 (USD MILLION) 143
TABLE 116 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 117 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 118 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 119 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY REGION, 2022–2030 (USD MILLION) 145
TABLE 120 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 145
TABLE 121 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 146
TABLE 122 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 146
TABLE 123 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 148
TABLE 124 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION,
2022–2030 (USD MILLION) 149
TABLE 125 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 126 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 127 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2022–2030 (USD MILLION) 150
TABLE 128 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS,
BY REGION, 2022–2030 (USD MILLION) 151
TABLE 129 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 130 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 131 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 132 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2030 (USD MILLION) 153
TABLE 133 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 134 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 135 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 136 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER
END USERS, BY REGION, 2022–2030 (USD MILLION) 155
TABLE 137 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 138 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 139 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 140 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 158
TABLE 141 MACROECONOMIC INDICATORS FOR NORTH AMERICA 159
TABLE 142 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 161
TABLE 143 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 161
TABLE 144 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 162
TABLE 145 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 162
TABLE 146 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 163
TABLE 147 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 163
TABLE 148 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 164
TABLE 149 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 165
TABLE 150 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 166
TABLE 151 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 166
TABLE 152 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 167
TABLE 153 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 167
TABLE 154 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 168
TABLE 155 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 169
TABLE 156 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 170
TABLE 157 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 170
TABLE 158 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 171
TABLE 159 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 171
TABLE 160 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 172
TABLE 161 MACROECONOMIC INDICATORS FOR EUROPE 173
TABLE 162 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 174
TABLE 163 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 174
TABLE 164 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 175
TABLE 165 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 175
TABLE 166 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 176
TABLE 167 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 176
TABLE 168 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 177
TABLE 169 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 178
TABLE 170 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 179
TABLE 171 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 179
TABLE 172 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 180
TABLE 173 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 180
TABLE 174 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 181
TABLE 175 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 182
TABLE 176 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 182
TABLE 177 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 183
TABLE 178 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 183
TABLE 179 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 184
TABLE 180 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 184
TABLE 181 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 185
TABLE 182 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 186
TABLE 183 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 186
TABLE 184 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 187
TABLE 185 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 187
TABLE 186 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 188
TABLE 187 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 189
TABLE 188 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 190
TABLE 189 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 190
TABLE 190 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 191
TABLE 191 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 191
TABLE 192 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 192
TABLE 193 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 193
TABLE 194 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 193
TABLE 195 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 194
TABLE 196 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 194
TABLE 197 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 195
TABLE 198 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 195
TABLE 199 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 196
TABLE 200 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 197
TABLE 201 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 197
TABLE 202 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 198
TABLE 203 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 198
TABLE 204 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 199
TABLE 205 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 199
TABLE 206 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 201
TABLE 207 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 201
TABLE 208 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 202
TABLE 209 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 202
TABLE 210 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 203
TABLE 211 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 203
TABLE 212 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 204
TABLE 213 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 205
TABLE 214 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 206
TABLE 215 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 206
TABLE 216 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 207
TABLE 217 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 207
TABLE 218 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 208
TABLE 219 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 209
TABLE 220 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 210
TABLE 221 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 210
TABLE 222 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 211
TABLE 223 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 211
TABLE 224 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 212
TABLE 225 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2022–2030 (USD MILLION) 213
TABLE 226 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2022–2030 (USD MILLION) 214
TABLE 227 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 214
TABLE 228 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2022–2030 (USD MILLION) 215
TABLE 229 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY BIOLOGICS, 2022–2030 (USD MILLION) 215
TABLE 230 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 216
TABLE 231 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 217
TABLE 232 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 217
TABLE 233 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 218
TABLE 234 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 218
TABLE 235 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 219
TABLE 236 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 219
TABLE 237 MACROECONOMIC INDICATORS FOR LATIN AMERICA 221
TABLE 238 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 221
TABLE 239 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 222
TABLE 240 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 222
TABLE 241 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 223
TABLE 242 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 223
TABLE 243 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 224
TABLE 244 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA 225
TABLE 245 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION) 226
TABLE 246 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION) 226
TABLE 247 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 227
TABLE 248 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION) 227
TABLE 249 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION) 228
TABLE 250 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 228
TABLE 251 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022–2025 229
TABLE 252 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
DEGREE OF COMPETITION 233
TABLE 253 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
REGION FOOTPRINT 240
TABLE 254 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT TYPE FOOTPRINT 241
TABLE 255 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT 242
TABLE 256 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PHASE FOOTPRINT 243
TABLE 257 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 246
TABLE 258 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 247
TABLE 259 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 248
TABLE 260 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEALS, JANUARY 2022–JANUARY 2025 249
TABLE 261 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: EXPANSIONS, JANUARY 2022–JANUARY 2025 250
TABLE 262 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025 250
TABLE 263 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 251
TABLE 264 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 252
TABLE 265 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2022–
JANUARY 2025 253
TABLE 266 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JANUARY 2025 253
TABLE 267 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JANUARY 2025 254
TABLE 268 IQVIA: COMPANY OVERVIEW 255
TABLE 269 IQVIA: PRODUCTS/SERVICES OFFERED 256
TABLE 270 IQVIA: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 257
TABLE 271 IQVIA: DEALS, JANUARY 2022–JANUARY 2025 258
TABLE 272 ICON PLC: COMPANY OVERVIEW 259
TABLE 273 ICON PLC: PRODUCTS/SERVICES OFFERED 260
TABLE 274 ICON PLC: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025 260
TABLE 275 ICON PLC: DEALS, JANUARY 2022–JANUARY 2025 261
TABLE 276 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 262
TABLE 277 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 263
TABLE 278 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025 264
TABLE 279 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JANUARY 2025 265
TABLE 280 LABCORP: COMPANY OVERVIEW 266
TABLE 281 LABCORP: PRODUCTS/SERVICES OFFERED 267
TABLE 282 LABCORP: PRODUCTS LAUNCHES, JANUARY 2022–JANUARY 2025 268
TABLE 283 LABCORP: DEALS, JANUARY 2022–JANUARY 2025 268
TABLE 284 LABCORP: EXPANSIONS, JANUARY 2022–JANUARY 2025 269
TABLE 285 LABCORP: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025 269
TABLE 286 QUEST DIAGNOSTICS: COMPANY OVERVIEW 271
TABLE 287 QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED 272
TABLE 288 QUEST DIAGNOSTICS: DEALS, JANUARY 2022–JANUARY 2025 272
TABLE 289 MEDPACE: COMPANY OVERVIEW 274
TABLE 290 MEDPACE: PRODUCTS/SERVICES OFFERED 275
TABLE 291 MEDPACE: EXPANSIONS, JANUARY 2022–JANUARY 2025 275
TABLE 292 FRONTAGE LABS: COMPANY OVERVIEW 276
TABLE 293 FRONTAGE LABS: PRODUCTS/SERVICES OFFERED 277
TABLE 294 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW 279
TABLE 295 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED 280
TABLE 296 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: DEALS, JANUARY 2022–
JANUARY 2025 281
TABLE 297 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 282
TABLE 298 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 283
TABLE 299 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–JANUARY 2025 284
TABLE 300 REPROCELL INC.: COMPANY OVERVIEW 285
TABLE 301 REPROCELL INC.: PRODUCTS/SERVICES OFFERED 285
TABLE 302 REPROCELL INC.: DEALS, JANUARY 2022–JANUARY 2025 286
TABLE 303 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW 287
TABLE 304 ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED 287
TABLE 305 ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025 288
TABLE 306 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 289
TABLE 307 VERSITI: COMPANY OVERVIEW 290
TABLE 308 CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW 291
TABLE 309 CLARITY LABORATORIES, INC: COMPANY OVERVIEW 292
TABLE 310 NOVOTECH: COMPANY OVERVIEW 293
TABLE 311 ARUP LABORATORIES: COMPANY OVERVIEW 294
TABLE 312 PRECISION MEDICINE GROUP: COMPANY OVERVIEW 295
TABLE 313 BIOAGILYTIX LABS: COMPANY OVERVIEW 296
TABLE 314 CERBA HEALTHCARE: COMPANY OVERVIEW 297
TABLE 315 ALMAC GROUP: COMPANY OVERVIEW 298
TABLE 316 MLM MEDICAL LABS: COMPANY OVERVIEW 299
TABLE 317 SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW 300
TABLE 318 UNILABS: COMPANY OVERVIEW 301
LIST OF FIGURES
FIGURE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE 32
FIGURE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RESEARCH DESIGN 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
FIGURE 4 COMPANY REVENUE ESTIMATION APPROACH: BOTTOM-UP APPROACH 41
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: TOP-DOWN APPROACH 42
FIGURE 7 DATA TRIANGULATION METHODOLOGY 44
FIGURE 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION) 47
FIGURE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 49
FIGURE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION) 49
FIGURE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 51
FIGURE 14 INCREASING PREVALENCE OF RARE DISEASES TO DRIVE MARKET 52
FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024 53
FIGURE 16 CHINA TO RECORD HIGHEST GROWTH RATE FROM 2025 TO 2030 54
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 55
FIGURE 18 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64
FIGURE 20 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
VALUE CHAIN ANALYSIS 66
FIGURE 21 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
ECOSYSTEM ANALYSIS 67
FIGURE 22 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
INVESTMENT AND FUNDING SCENARIO, 2022−2025 68
FIGURE 23 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 81
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 83
FIGURE 25 KEY BUYING CRITERIA, BY END USER 84
FIGURE 26 AI USE CASES 86
FIGURE 27 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT 160
FIGURE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT 200
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION) 232
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 233
FIGURE 31 RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2024 234
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 235
FIGURE 33 FINANCIAL METRICS, 2025 235
FIGURE 34 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON 236
FIGURE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 238
FIGURE 36 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY FOOTPRINT 239
FIGURE 37 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 245
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 252
FIGURE 39 IQVIA: COMPANY SNAPSHOT (2024) 256
FIGURE 40 ICON PLC: COMPANY SNAPSHOT (2023) 259
FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023) 263
FIGURE 42 LABCORP: COMPANY SNAPSHOT (2024) 267
FIGURE 43 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024) 271
FIGURE 44 MEDPACE: COMPANY SNAPSHOT (2024) 274
FIGURE 45 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 277
FIGURE 46 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024) 280
FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 283
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11